Fighting Antibiotic-resistant Bacteria via Biofilm Prevention
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Life Matters is a preclinical-stage biopharmaceutical company focused on tackling antibiotic-resistant bacteria. The company has developed a new solution for fighting the resistant bacteria often acquired in hospitals by preventing the bacterias biofilm mode of growth, resulting in a more treatable infection.
Morbidity and mortality in chronic lung infections are often tied to biofilm-related P. aeruginosa. Eliminating the bacterial biofilm enables the innate immune system to eradicate the infection. Life Matters small molecules do not possess any resistance-creating selective pressure, and its compounds are effective against a wide variety of gram negative and positive pathogens.
The companys lead product is API, IBF-2, a compound with an innovative mechanism of action that can attenuate the biofilm mode of growth, a crucial phenotype that allows bacteria to survive environmental stresses such as antibacterial agents or the hosts immune system.